CRDF NASDAQ
Cardiff Oncology, Inc.
1W: +3.5%
1M: +3.5%
3M: +11.2%
YTD: -32.7%
1Y: -41.7%
3Y: +5.3%
5Y: -79.1%
$1.78
-0.01 (-0.56%)
Weekly Expected Move ±8.2%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
Articles (1)
-0.45
Bearish
0 bullish
1 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (33)
CRDF: First Quarter 2026 Results
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Consensus Target Price from Analysts
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Cardiff Oncology (NASDAQ:CRDF) Trading Down 1.1% – Here’s What Happened
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Cardiff Oncology appoints Mani Mohindru as CEO
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
CRDF: Colorectal Cancer KOL Event
Noble Financial Issues Optimistic Estimate for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Consensus PT from Analysts
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Blair William & Co. IL Has $4.56 Million Stock Position in Cardiff Oncology, Inc. $CRDF
What is Zacks Research’s Forecast for CRDF FY2027 Earnings?
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Consensus Target Price from Analysts
CRDF: 10-K Filing Prompts Model Update
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology GAAP EPS of -$0.69 beats by $0.08, revenue of $0.59M beats by $0.14M
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Average Target Price from Brokerages
Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.63 Average Price Target from Analysts
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference